2016 GA agenda item 6.7 EMVO membership

Return to 2016 GA agenda page here.

As will be familiar to GA delegates from the previous 3 year’s assemblies, and the past two Members’ Meetings in Vienna and Hamburg, an open question that has been under consideration by the EAHP Board is whether EAHP should join the European Medicines Verification Organisation (EMVO) in order to better influence implementation development in respect to the Falsified Medicines Directive.

Since the 2015 General Assembly the financial implications of such a decision have been made clearer. See table below

Strategic Option	Cost
Join the European Medicines Verification Organisation as a full member	80,000 euros per year (plus associated costs e.g. travel to meetings etc)
Join the European Medicines Verification Organisation as an associate member	20,000 euros per year (plus associated costs e.g. travel to meetings etc)
Remain outside of the European Medicines Verification Organisation	No cost

At the April 2016 Board Meeting, a majority of the Board favoured NOT joining the European Medicines Verification Organisation, pursuing a process of complaint about the Directive with the European Ombudsman, and depending on the outcome achieved, reviewing the case for associate membership of EMVO at the January 2017 Board Meeting.

For a fuller summary of the Board’s considerations on these issues, including summary slides weighing up the pros and cons of the different options, visit the ‘FMD representation’ section of Agenda item 7.8 here.

The above figures are supplied to members to assist their considerations on the financial impacts of the options before EAHP.

For further information on this topic refer to agenda item 7.8 Falsified Medicines Directive and implementation.

See also presentation slides and written report of Members Meeting 2016 here, and Members Meeting 2015 here.